--- title: Collagen Peptides and Cellular Aging nct_id: NCT07456449 overall_status: RECRUITING phase: NA sponsor: University of Vienna study_type: INTERVENTIONAL primary_condition: Longevity countries: Austria canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07456449.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07456449" ct_last_update_post_date: 2026-05-05 last_seen_at: "2026-05-12T07:30:53.785Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Collagen Peptides and Cellular Aging **Official Title:** Collagen Peptides and Cellular Aging: a Randomized, Placebo-controlled Intervention Study on Telomere Length, Inflammation, Body Composition, and Functional Capacity in Middle-aged and Older Adults **NCT ID:** [NCT07456449](https://clinicaltrials.gov/study/NCT07456449) ## Key Facts - **Status:** RECRUITING - **Phase:** NA - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 125 - **Lead Sponsor:** University of Vienna - **Collaborators:** CRI Collagen Research Institute GmbH - **Conditions:** Longevity, Healthy Aging, Biological Ageing - **Start Date:** 2026-04-22 - **Completion Date:** 2028-08 - **CT.gov Last Update:** 2026-05-05 ## Brief Summary The goal of this clinical trial is to learn if daily collagen peptide supplementation can stabilize or lengthen telomeres and improve related markers of cellular aging in adults aged 50-70 years with overweight and low-to-moderate physical activity (healthy volunteers without major chronic disease). Main questions it aims to answer are: Does six months of collagen peptides stabilize or extend telomere length and increase telomerase activity compared with placebo? Are any telomere-related changes associated with lower inflammation, healthier body composition, and better functional health? Researchers will compare collagen as an intervention to a placebo group to see if collagen will influence aging markers. Participants will take collagen peptides or a placebo daily for 24 weeks. They will attend three study visits: one before starting the intervention (T0), one at 3 months (T1), and one at 6 months (T2). At each visit, blood samples will be collected to measure telomere length, telomerase activity, and inflammation/redox markers. Participants will also undergo body composition assessments using bioelectrical impedance, complete functional tests of muscle strength and mobility, and fill out questionnaires on health and vitality. ## Eligibility - **Minimum age:** 50 Years - **Maximum age:** 70 Years - **Sex:** ALL - **Healthy Volunteers:** Yes ``` Inclusion Criteria: * Adults aged 50-70 years; both male and female participants are eligible * Body mass index (BMI) 25-30 kg/m² * Low to moderate physical activity: not meeting current WHO recommendations (\<150 minutes/week) or ≤2 sessions/week structured training * Able to live independently and mobile in daily life * No regular resistance training within the past 6 months * Provision of written informed consent Exclusion Criteria: * Diagnosed chronic diseases relevant to the immune system, metabolism, or cellular aging (e.g., diabetes mellitus, cancer, cardiovascular, rheumatologic diseases) * Use of immunomodulatory, systemic anti-inflammatory, or hormonal medications (e.g., corticosteroids, immunosuppressants) * Acute infections or surgeries within the last 3 months * Regular use of supplements known to affect oxidative stress or cellular aging (e.g., high-dose antioxidants, CoQ10, omega-3 fatty acids, high-dose vitamin D) * Participation in another clinical study within the last 3 months * Vegetarian or vegan diet (product contains animal-derived collagen) ``` ## Arms - **Collagen Peptides** (EXPERIMENTAL) — Participants receive daily oral supplementation with specific collagen peptides for 24 weeks. Allocation is randomized 1:1 and double-blinded against placebo. Study visits occur at baseline (T0), 3 months (T1), and 6 months (T2). Blood samples are collected to assess telomere length (qPCR T/S ratio) and telomerase activity (TRAP), alongside inflammation and redox markers. Body composition (bioelectrical impedance), functional tests (muscle strength, mobility), and questionnaires on health and vitality are also performed. The intervention aims to test whether six months of collagen peptides stabilize or extend telomeres and increase telomerase activity compared with placebo. - **Maltodextrin** (PLACEBO_COMPARATOR) — Participants receive a daily placebo matched in a double-blind design for 24 weeks, with the same schedule of study visits at T0, T1, and T2 and the same assessments (blood biomarkers of telomere biology, inflammation/redox; body composition; functional tests; questionnaires) as the verum arm. Maltodextrin serves as the control to compare effects against collagen peptides in a randomized, double-blind, placebo-controlled, parallel-group trial. ## Interventions - **Collagen peptides** (DIETARY_SUPPLEMENT) — Collagen peptides (oral daily supplementation), taken once daily for 24 weeks in a randomized 1:1, double-blind design; primary outcomes: telomere length (qPCR T/S) and telomerase activity (TRAP), with inflammatory/redox markers as secondary endpoints. Target population: adults 50-70 years with BMI 25-30 and low-to-moderate activity; vegetarians/vegans excluded due to animal-derived collagen. Matched maltodextrin placebo, identical dosing and visit schedule (T0, T1, T2), serving as the comparator to isolate collagen peptide effects in the parallel-group, double-blind trial. Products are approved as foods; prior clinical studies reported no substance-related adverse effects. - **Maltodextrin (Placebo)** (DIETARY_SUPPLEMENT) — Placebo instead of the collagen peptides ## Primary Outcomes - **Telomere length** _(time frame: Baseline and after supplementation (24 weeks))_ — Changes in leukocyte telomere length (qPCR) from peripheral blood - **Telomerase Activity** _(time frame: Baseline and at the end of supplemention (24 weeks))_ — Changes telomerase activity measured via TRAP Assay from peripheral blood - **Change from baseline in DNA-oxidation markers** _(time frame: Baseline and at the end of supplementation (24 weeks))_ — Change in DNA Damage measured through comet assay - **Change from baseline in micronuclei** _(time frame: Baseline and at the end of supplementation (24 weeks))_ — Change in Micronulei measured through CBMN-Assay ## Secondary Outcomes - **Change from baseline in Inflammatory markers** _(time frame: Baseline and at the end of supplemention (24 weeks))_ - **Change from baseline in the redox/antioxidant status** _(time frame: Baseline and at the end of supplementation (24 weeks))_ - **Change from baseline in body composition** _(time frame: Basline, after 3 months and at the end of the supplementation (24 weeks))_ - **Change from baseline metabolic markers** _(time frame: Baseline and at the end of supplementation (24 weeks))_ - **Change from baseline in hormonal markers** _(time frame: Baseline and at the end of supplementation (24 weeks))_ - **Change from baseline in muscle strength** _(time frame: Baseline, after 3 months and at the end of supplementation (24 weeks))_ - **Change from baseline in dietary intake** _(time frame: Baseline, after 3 months and at the end of supplementation (24 weeks))_ - **Change from baseline in patient-reported outcomes like quality of life** _(time frame: Baseline, after 3 months and at the end of supplementation (24 weeks))_ - **Change of phase angle** _(time frame: Basline, after 3 months and at the end of the supplementation (24 weeks))_ - **Change from baseline in Insulin** _(time frame: Baseline and at the end of supplementation (24 weeks))_ - **Change from baseline in patient-reported outcomes like sleep quality** _(time frame: Baseline, after 3 months and at the end of supplementation (24 weeks))_ - **Change from baseline in patient-reported outcomes like health** _(time frame: Baseline, after 3 months and at the end of supplementation (24 weeks))_ - **Change from baseline in patient-reported outcomes like fatigue** _(time frame: Baseline, after 3 months and at the end of supplementation (24 weeks))_ - **Change from baseline in oxidative stress** _(time frame: Baseline and at the end of supplementation (24 weeks))_ ## Locations (1) - University of Vienna, NuTraLab, Vienna, State of Vienna, Austria — _RECRUITING_ ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.maxAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `sponsor.collaborators` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.university of vienna, nutralab|vienna|state of vienna|austria` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT07456449.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT07456449* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*